DAFTAR PUSTAKA

Adams, J. M., & Cory, S. (2017). The BCL-2 arbiters of apoptosis and their growing role as cancer targets. *Cell Death and Differentiation*, *25*(1), 27–36. https://doi.org/10.1038/cdd.2017.161

Akwarini, F., Fadjari, T. H., & Hernowo, B. S. (2019). Triple negative breast cancer characteristics based on Basal-like and Non-Basal-like subtypes. *DOAJ (DOAJ: Directory of Open Access Journals)*. https://doi.org/10.15850/ijihs.v7n1.1570

Alghamian, Y., Soukkarieh, C., Abbady, A. Q., & Murad, H. (2022). Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line. *Scientific Reports*, *12*(1). https://doi.org/10.1038/s41598-022-11634-6

Alshehade, S. A., Almoustafa, H. A., Alshawsh, M. A., & Chik, Z. (2024). Flow cytometry-based quantitative analysis of cellular protein expression in apoptosis subpopulations: A protocol. *Heliyon*, *10*(13), e33665. https://doi.org/10.1016/j.heliyon.2024.e33665

Amaro, A., Angelini, G., Mirisola, V., Esposito, A. I., Reverberi, D., Matis, S., Maffei, M., Giaretti, W., Viale, M., Gangemi, R., Emionite, L., Astigiano, S., Cilli, M., Bachmeier, B. E., Killian, P. H., Albini, A., & Pfeffer, U. (2016). A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicityin vivo. *Oncotarget*, *7*(42), 68803–68820. https://doi.org/10.18632/oncotarget.11931

Andón, F. T., & Fadeel, B. (2012). Programmed cell death: Molecular mechanisms and implications for safety assessment of nanomaterials. *Accounts of Chemical Research*, *46*(3), 733–742. https://doi.org/10.1021/ar300020b

Andrés, C. M. C., De La Lastra, J. M. P., Munguira, E. B., Juan, C. A., & Pérez-Lebeña, E. (2024). Dual-Action therapeutics: DNA alkylation and antimicrobial peptides for cancer therapy. *Cancers*, *16*(18), 3123. https://doi.org/10.3390/cancers16183123

Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020). MicroRNAs biogenesis, functions and role in tumor angiogenesis. *Frontiers in Oncology*, *10*. https://doi.org/10.3389/fonc.2020.581007

Ardiyan, Y. N., & Pratiwi, J. P. D. (2024). Biogenesis and function of miRNAs and their role in cancer. *Jurnal Impresi Indonesia*, *3*(6), 404–410. https://doi.org/10.58344/jii.v3i6.4974

Arya, S. B., Collie, S. P., & Parent, C. A. (2023). The ins-and-outs of exosome biogenesis, secretion, and internalization. *Trends in Cell Biology*, *34*(2), 90–108. https://doi.org/10.1016/j.tcb.2023.06.006

Asghariazar, V., Kadkhodayi, M., Sarailoo, M., Jolfayi, A. G., & Baradaran, B. (2023). MicroRNA-143 as a potential *tumor suppressor* in cancer: An insight into molecular targets and signaling pathways. *Pathology - Research and Practice*, *250*, 154792. https://doi.org/10.1016/j.prp.2023.154792

Aysola, K., Desai, A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech, D. J., Piyathilake, C. J., Reddy, S. P., & Rao, V. N. (2012). Triple negative breast cancer – an overview. *Hereditary Genetics*. https://doi.org/10.4172/2161-1041.s2-001

Balaraman, A. K., Babu, M. A., Afzal, M., Sanghvi, G., M, R. M., Gupta, S., Rana, M., Ali, H., Goyal, K., Subramaniyan, V., Wong, L. S., & Kumarasamy, V. (2025). Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells. *Regenerative Therapy*, *28*, 558–572. https://doi.org/10.1016/j.reth.2025.01.019

Barchiesi, G., Roberto, M., Verrico, M., Vici, P., Tomao, S., & Tomao, F. (2021). Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives. *Frontiers in Oncology*, *11*. https://doi.org/10.3389/fonc.2021.769280

Bertheloot, D., Latz, E., & Franklin, B. S. (2021). Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. *Cellular and Molecular Immunology*, *18*(5), 1106–1121. https://doi.org/10.1038/s41423-020-00630-3

Bhatavdekar, O., Godet, I., Gilkes, D., & Sofou, S. (2022). The rate of Cisplatin dosing affects the resistance and metastatic potential of triple negative breast cancer cells, independent of hypoxia. *Pharmaceutics*, *14*(10), 2184. https://doi.org/10.3390/pharmaceutics14102184

Birkelbach, M., Ferraiolo, N., Gheorghiu, L., Pfäffle, H. N., Daly, B., Ebright, M. I., Spencer, C., O'Hara, C., Whetstine, J. R., Benes, C. H., Sequist, L. V., Zou, L., Dahm-Daphi, J., Kachnic, L. A., & Willers, H. (2013). Detection of impaired homologous recombination repair in NSCLC cells and tissues. *Journal of Thoracic Oncology*, *8*(3), 279–286. https://doi.org/10.1097/jto.0b013e31827ecf83

Błaszczak, E., Miziak, P., Odrzywolski, A., Baran, M., Gumbarewicz, E., & Stepulak, A. (2025). Triple-Negative breast cancer progression and drug resistance in the context of Epithelial–Mesenchymal Transition. *Cancers*, *17*(2), 228. https://doi.org/10.3390/cancers17020228

Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F., Proudhon, C., . . . Gonçalves, A. (2016). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Annals of Oncology*, *27*(5), 812–818. https://doi.org/10.1093/annonc/mdw067

Brezgin, S., Danilik, O., Yudaeva, A., Kachanov, A., Kostyusheva, A., Karandashov, I., Ponomareva, N., Zamyatnin, A. A., Parodi, A., Chulanov, V., & Kostyushev, D. (2024). Basic Guide for Approaching Drug Delivery with Extracellular Vesicles. *International Journal of Molecular Sciences*, *25*(19), 10401. https://doi.org/10.3390/ijms251910401

Brooks, E. A., Galarza, S., Gencoglu, M. F., Cornelison, R. C., Munson, J. M., & Peyton, S. R. (2019). Applicability of drug response metrics for cancer studies using biomaterials. *Philosophical Transactions of the Royal Society B Biological Sciences*, *374*(1779), 20180226. https://doi.org/10.1098/rstb.2018.0226

Buranaamnuay, K. (2021). The MTT assay application to measure the viability of spermatozoa: a variety of the assay protocols. *Open Veterinary Journal*, *11*(2), 251. https://doi.org/10.5455/ovj.2021.v11.i2.9

Cai, Y., Tan, X., Liu, J., Shen, Y., Wu, D., Ren, M., Huang, P., & Yu, D. (2014). Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. *pmc.ncbi.nlm.nih.gov*. https://doi.org/10.3978/j.issn.1000-9604.2014.08.20

Chavda, V. P., Pandya, A., Kumar, L., Raval, N., Vora, L. K., Pulakkat, S., Patravale, V., Salwa, N., Duo, Y., & Tang, B. Z. (2023). Exosome nanovesicles: A potential carrier for therapeutic delivery. *Nano Today*, *49*, 101771. https://doi.org/10.1016/j.nantod.2023.101771

Chen, H. H. W., & Kuo, M. T. (2010). Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. *Metal-Based Drugs*, *2010*, 1–7. https://doi.org/10.1155/2010/430939

Chen, T., Xu, M., Xu, J., Zhan, X., Zhang, Y., Ying, M., & Wu, M. (2024). The application of immunotherapy combined with taxanes in second-line treatment of advanced HER2 negative gastric cancer. *Molecular and Clinical Oncology*, *22*(1). https://doi.org/10.3892/mco.2024.2806

Chen, X., Qian, X., Xiao, M., & Zhang, P. (2023). Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study. *Breast Cancer Targets and Therapy*, *Volume 15*, 671–682. https://doi.org/10.2147/bctt.s423330

Chen, Y., Li, X., Yang, M., & Liu, S. (2024). Research progress on morphology and mechanism of programmed cell death. *Cell Death and Disease*, *15*(5). https://doi.org/10.1038/s41419-024-06712-8

Cheng, T., Hu, C., Yang, H., Cao, L., & An, J. (2014). Transforming growth factor-β-induced miR-143 expression in regulation of non-small cell lung cancer cell viability and invasion capacity in vitro and in vivo. *International Journal of Oncology*, *45*(5), 1977–1988. https://doi.org/10.3892/ijo.2014.2623

Comfort, N., Cai, K., Bloomquist, T. R., Strait, M. D., Ferrante, A. W., Jr, & Baccarelli, A. A. (2021). Nanoparticle tracking analysis for the quantification and size determination of extracellular vesicles. *Journal of Visualized Experiments*, *169*. https://doi.org/10.3791/62447

Conara, F. C., Oktavya, G., Purwestri, Y. A., & Nuriliani, A. (2023). Effect of black rice bran ‘Sembada Hitam’ on T47D breast cancer cells. *Journal of Tropical Life Science*, *13*(3), 589–598. https://doi.org/10.11594/jtls.13.03.17

Cordonnier, M., Chanteloup, G., Isambert, N., Seigneuric, R., Fumoleau, P., Garrido, C., & Gobbo, J. (2017). Exosomes in cancer theranostic:

Diamonds in the rough. *Cell Adhesion & Migration*, *11*(2), 151–163. https://doi.org/10.1080/19336918.2016.1250999

Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., Bacher, P., Bari, S., Barnaba, V., Barros-Martins, J., Baumjohann, D., Beccaria, C. G., Bernardo, D., Boardman, D. A., Borger, J., . . . Yang, J. (2021). Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). *European Journal of Immunology*, *51*(12), 2708–3145. https://doi.org/10.1002/eji.202170126

Da Silvia Lima, R. Q., Vasconcelos, C. F. M., Gomes, J. P. A., Da Silva Bezerra De Menezes, E., De Oliveira Silva, B., Montenegro, C., De Sá Leitão Paiva Júnior, S., & Pereira, M. C. (2024). miRNA-21, an OncomiR that regulates cell proliferation, migration, invasion and therapy response in lung cancer. *Pathology - Research and Practice*, *263*, 155601. https://doi.org/10.1016/j.prp.2024.155601

Damasuri, N. a. R., Sholikhah, N. E. N., & Mustofa, N. (2020). Cytotoxicity of ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) on HeLa cell line. *Indonesian Journal of Pharmacology and Therapy*, *1*(2). https://doi.org/10.22146/ijpther.606

Darvishi, M., Esmaeili, S., Dehghan-Nayeri, N., Mashati, P., & Gharehbaghian, A. (2017). Anticancer effect and enhancement of therapeutic potential of Vincristine by extract from aerial parts of Juniperus excelsa on pre-B acute lymphoblastic leukemia cell lines. *Journal of Applied Biomedicine*, *15*(3), 219–226. https://doi.org/10.1016/j.jab.2017.04.002

Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*, *740*, 364–378. https://doi.org/10.1016/j.ejphar.2014.07.025

De Abreu, R. C., Ramos, C. V., Becher, C., Lino, M., Jesus, C., Da Costa Martins, P. A., Martins, P. a. T., Moreno, M. J., Fernandes, H., & Ferreira, L. (2021). Exogenous loading of miRNAs into small extracellular vesicles. *Journal of Extracellular Vesicles*, *10*(10). https://doi.org/10.1002/jev2.12111

De Faria Bessa, J., & Marta, G. N. (2022). Triple-negative breast cancer and radiation therapy. *Reports of Practical Oncology & Radiotherapy*. https://doi.org/10.5603/rpor.a2022.0025

Deng, Y. W., Hao, W. J., Li, Y. W., Li, Y. X., Zhao, B. C., & Lu, D. (2018). HSA-MiRNA-143-3P reverses multidrug resistance of Triple-Negative breast cancer by inhibiting the expression of its target protein Cytokine-Induced apoptosis inhibitor 1In vivo. *Journal of Breast Cancer*, *21*(3), 251. https://doi.org/10.4048/jbc.2018.21.e40

Dewi, C., Fristiohady, A., Amalia, R., Ikram, N. K. K., Ibrahim, S., & Muchtaridi, M. (2022). Signaling pathways and natural compounds in Triple-Negative Breast Cancer cell line. *Molecules*, *27*(12), 3661. https://doi.org/10.3390/molecules27123661

Dilsiz, N. (2024). A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications. *Translational Oncology*, *50*, 102121. https://doi.org/10.1016/j.tranon.2024.102121

Ding, L., Gu, H., Xiong, X., Ao, H., Cao, J., Lin, W., Yu, M., Lin, J., & Cui, Q. (2019). MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance, and applications in human Triple-Negative breast cancer. *Cells*, *8*(12), 1492. https://doi.org/10.3390/cells8121492

Duan, Z., Cai, G., Li, J., & Chen, X. (2020). Cisplatin-induced renal toxicity in elderly people. *Therapeutic Advances in Medical Oncology*, *12*. https://doi.org/10.1177/1758835920923430

Ellistasari, E. Y., Kariosentono, H., Purwanto, B., Wasita, B., Riswiyant, R. C. A., Pamungkasari, E. P., & Soetrisno, S. (2022). Exosomes Derived from Secretome Human Umbilical Vein Endothelial Cells (Exo-HUVEC) Ameliorate the Photo-Aging of Skin Fibroblast. *Clinical Cosmetic and Investigational Dermatology*, *Volume 15*, 1583–1591. https://doi.org/10.2147/ccid.s371330

Elmorsy, E. A., Saber, S., Hamad, R. S., Abdel-Reheim, M. A., El-Kott, A. F., AlShehri, M. A., Morsy, K., Salama, S. A., & Youssef, M. E. (2024). Advances in Understanding Cisplatin-Induced Toxicity: Molecular mechanisms and protective strategies. *European Journal of Pharmaceutical Sciences*, 106939. https://doi.org/10.1016/j.ejps.2024.106939

Ensenyat-Mendez, M., Llinàs-Arias, P., Orozco, J. I. J., Íñiguez-Muñoz, S., Salomon, M. P., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021). Current Triple-Negative Breast Cancer subtypes: dissecting the most aggressive form of breast cancer. *Frontiers in Oncology*, *11*. https://doi.org/10.3389/fonc.2021.681476

Fasril, T., Hilbertina, N., & Elliyanti, A. (2023). Treatment problems in triple negative breast cancer. *International Islamic Medical Journal*, *4*(2), 51–58. https://doi.org/10.33086/iimj.v4i2.3951

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & Diseases*, *5*(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001

Fernández-Lázaro, D., Sanz, B., & Seco-Calvo, J. (2024). The Mechanisms of Regulated cell death: Structural and functional proteomic pathways induced or inhibited by a specific Protein—A Narrative review. *Proteomes*, *12*(1), 3. https://doi.org/10.3390/proteomes12010003

Fertilita, S., Sandhika, W., & Suprabawati, D. G. A. (2020). The Cytotoxic Activity of Annona muricata Linn Leaves Ethanolic Extract (AMEE) on T47D Breast Cancer Cell Line. *Medical Laboratory Technology Journal*, *6*(1). https://doi.org/10.31964/mltj.v6i1.291

Fu, Y., Yang, Q., Yang, H., & Zhang, X. (2023). New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer.

Frontiers in Molecular Biosciences, *10*. https://doi.org/10.3389/fmolb.2023.1162463

Galletti, G., Zhang, C., Gjyrezi, A., Cleveland, K., Zhang, J., Powell, S., Thakkar, P. V., Betel, D., Shah, M. A., & Giannakakou, P. (2020). Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. *Clinical Cancer Research*, *26*(14), 3771–3783. https://doi.org/10.1158/1078-0432.ccr-19-3018

Geisberg, C. A., & Sawyer, D. B. (2010). Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. *Current Hypertension Reports*, *12*(6), 404–410. https://doi.org/10.1007/s11906-010-0146-y

Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell analysis. *International Journal of Molecular Sciences*, *22*(23), 12827. https://doi.org/10.3390/ijms222312827

Gibalová, L., Šereš, M., Rusnák, A., Ditte, P., Labudová, M., Uhrík, B., Pastorek, J., Sedlák, J., Breier, A., & Sulová, Z. (2012). P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. *Toxicology in Vitro*, *26*(3), 435–444. https://doi.org/10.1016/j.tiv.2012.01.014

González-González, A., García-Sánchez, D., Dotta, M., Rodríguez-Rey, J. C., & Pérez-Campo, F. M. (2020). Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. *World Journal of Stem Cells*, *12*(12), 1529–1552. https://doi.org/10.4252/wjsc.v12.i12.1529

Grimm, L. J., Rahbar, H., Abdelmalak, M., Hall, A. H., & Ryser, M. D. (2021). Ductal carcinoma in situ: State-of-the-Art review. *Radiology*, *302*(2), 246–255. https://doi.org/10.1148/radiol.211839

Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015). Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. *Genes & Development*, *29*(5), 489–494. https://doi.org/10.1101/gad.256214.114

Hanahan, D. (2022). Hallmarks of Cancer: New dimensions. *Cancer Discovery*, *12*(1), 31–46. https://doi.org/10.1158/2159-8290.cd-21-1059

Haryana, S. M., Oktriani, R., Faiha, D. K., Conara, F. C., Dafip, M., & Setiasari, D. W. (2025). miR-143-3p: A Critical Regulator of KRAS and HRAS with Potential for Targeted Therapies in Breast Cancer. *Trends in Sciences*, *22*(7), 9630. https://doi.org/10.48048/tis.2025.9630

Hedley, B. D., & Keeney, M. (2013). Technical issues: flow cytometry and rare event analysis. *International Journal of Laboratory Hematology*, *35*(3), 344–350. https://doi.org/10.1111/ijlh.12068

Hero, T., Bühler, H., Kouam, P. N., Priesch-Grzeszowiak, B., Lateit, T., & Adamietz, I. A. (2019). The triple-negative breast cancer cell line MDA-MB 231 is specifically inhibited by the ionophore salinomycin. *Anticancer Research*, *39*(6), 2821–2827. https://doi.org/10.21873/anticanres.13410

Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016). The role of p53 in cancer drug resistance and targeted chemotherapy. *Oncotarget*, *8*(5), 8921–8946. https://doi.org/10.18632/oncotarget.13475

Hoang, V. T., Stępniewski, G., Czarnecka, K. H., Kasztelanic, R., Long, V. C., Xuan, K. D., Shao, L., Śmietana, M., & Buczyński, R. (2019). Optical properties of buffers and cell culture media for optofluidic and sensing applications. *Applied Sciences*, *9*(6), 1145. https://doi.org/10.3390/app9061145

Hou, Y., Feng, H., Jiao, J., Qian, L., Sun, B., Chen, P., Li, Q., & Liang, Z. (2019). Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7. *Artificial Cells Nanomedicine and Biotechnology*, *47*(1), 2065–2071. https://doi.org/10.1080/21691401.2019.1620252

Huang, Z., Yu, P., & Tang, J. (2020). Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model. *OncoTargets and Therapy*, *Volume 13*, 5395–5405. https://doi.org/10.2147/ott.s249756

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015). Biochemical and structural analysis of common Cancer-Associated KRAS mutations. *Molecular Cancer Research*, *13*(9), 1325–1335. https://doi.org/10.1158/1541-7786.mcr-15-0203

Huovinen, M., Loikkanen, J., Myllynen, P., & Vähäkangas, K. H. (2011). Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. *Toxicology in Vitro*, *25*(5), 1007–1017. https://doi.org/10.1016/j.tiv.2011.03.018

Isakoff, S. J. (2010). Triple-Negative breast cancer. *The Cancer Journal*, *16*(1), 53–61. https://doi.org/10.1097/ppo.0b013e3181d24ff7

Isert, L., Mehta, A., Loiudice, G., Oliva, A., Roidl, A., & Merkel, O. M. (2023). An in vitro approach to model EMT in breast cancer. *International Journal of Molecular Sciences*, *24*(9), 7757. https://doi.org/10.3390/ijms24097757

Janiczek-Polewska, M., Kolenda, T., Poter, P., Kozłowska-Masłoń, J., Jagiełło, I., Regulska, K., Malicki, J., & Marszałek, A. (2024). Diagnostic potential of MIR-143-5p, MiR-143-3p, MIR-551b-5p, and MIR-574-3p in chemoresistance of locally advanced gastric cancer: a preliminary study. *International Journal of Molecular Sciences*, *25*(15), 8057. https://doi.org/10.3390/ijms25158057

Jenie, R., Handayani, S., Susidarti, R. A., & Meiyanto, E. (2020). The Effect of Brazilin from Caesalpinia sappan on Cell Cycle and Modulation and Cell Senescence in T47D cells. *INDONESIAN JOURNAL OF PHARMACY*, *31*(2), 84. https://doi.org/10.14499/indonesianjpharm31iss2pp84

Jiang, W., Kong, L., Ni, Q., Lu, Y., Ding, W., Liu, G., Pu, L., Tang, W., & Kong, L. (2023). Correction: MIR-146A ameliorates liver Ischemia/Reperfusion injury by suppressing IRAK1 and TRAF6. *PLoS ONE*, *18*(7), e0288672. https://doi.org/10.1371/journal.pone.0288672

Johannessen, C., Moi, L., Kiselev, Y., Pedersen, M. I., Dalen, S. M., Braaten, T., & Busund, L. (2017). Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. *PLoS ONE*, *12*(10), e0186658. https://doi.org/10.1371/journal.pone.0186658

Karim, A. M., Kwon, J. E., Ali, T., Jang, J., Ullah, I., Lee, Y., Park, D. W., Park, J., Jeang, J. W., & Kang, S. C. (2023). Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. *Biochemical Pharmacology*, *212*, 115545. https://doi.org/10.1016/j.bcp.2023.115545

Kntayya, S. B., Ibrahim, M. D., Ain, N. M., Iori, R., Ioannides, C., & Razis, A. F. A. (2018). Induction of apoptosis and cytotoxicity by isothiocyanate sulforaphene in human hepatocarcinoma HEPG2 cells. *Nutrients*, *10*(6), 718. https://doi.org/10.3390/nu10060718

Ko, H., Lee, M., Cha, E., Sul, J., Park, J., & Lee, J. (2022). Eribulin mesylate improves Cisplatin-Induced cytotoxicity of Triple-Negative breast cancer by extracellular Signal-Regulated kinase 1/2 activation. *Medicina*, *58*(4), 547. https://doi.org/10.3390/medicina58040547

Koga, Y., Yasunaga, M., Moriya, Y., Akasu, T., Fujita, S., Yamamoto, S., & Matsumura, Y. (2011). Exosome can prevent RNase from degrading microRNA in feces. *PubMed*. https://doi.org/10.3978/j.issn.2078-6891.2011.015

Koh, M. Z., Ho, W. Y., Yeap, S. K., Ali, N. M., Boo, L., & Alitheen, N. B. (2021). Regulation of cellular and cancer stem Cell-Related Putative gene expression of parental and CD44+CD24− sorted MDA-MB-231 cells by Cisplatin. *Pharmaceuticals*, *14*(5), 391. https://doi.org/10.3390/ph14050391

Kučuk, N., Primožič, M., Knez, Ž., & Leitgeb, M. (2021). Exosomes engineering and their roles as therapy delivery tools, therapeutic targets, and biomarkers. *International Journal of Molecular Sciences*, *22*(17), 9543. https://doi.org/10.3390/ijms22179543

Lagunes, M. L. R., & Pezo, R. C. (2021). A narrative review of chemotherapy in advanced triple negative breast cancer. *Precision Cancer Medicine*, *4*, 13. https://doi.org/10.21037/pcm-20-69

Lai, X., & Friedman, A. (2016). Exosomal MIRs in Lung Cancer: a Mathematical Model. *PLoS ONE*, *11*(12), e0167706. https://doi.org/10.1371/journal.pone.0167706

Lakshmanan, I., & Batra, S. K. (2013). Protocol for apoptosis assay by flow cytometry using Annexin V staining method. *BIO-PROTOCOL*, *3*(6). https://doi.org/10.21769/bioprotoc.374

Lao, T. D., & Le, T. a. H. (2020). MicroRNAs: biogenesis, functions and potential biomarkers for early screening, prognosis and therapeutic molecular monitoring of nasopharyngeal carcinoma. *Processes*, *8*(8), 966. https://doi.org/10.3390/pr8080966

Li, D., Hu, J., Song, H., Xu, H., Wu, C., Zhao, B., Xie, D., Wu, T., Zhao, J., & Fang, L. (2017, May 15). miR-143-3p *targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells*. Retrieved July 18, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC5446510/

Li, L. (2022). Editorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy. *Frontiers in Cell and Developmental Biology*, *10*. https://doi.org/10.3389/fcell.2022.971477

Li, Y., Meng, L., Li, B., Li, Y., Shen, T., & Zhao, B. (2022). The Exosome Journey: From biogenesis to regulation and function in cancers. *Journal of Oncology*, *2022*, 1–13. https://doi.org/10.1155/2022/9356807

Liberati, F. R., Di Russo, S., Barolo, L., Peruzzi, G., Farina, M. V., Spizzichino, S., Di Fonzo, F., Quaglio, D., Pisano, L., Botta, B., Giorgi, A., Boffi, A., Cutruzzolà, F., Paone, A., & Baiocco, P. (2024). Combined Delivery of miR-15/16 through Humanized Ferritin Nanocages for the Treatment of Chronic Lymphocytic Leukemia. *Pharmaceutics*, *16*(3), 402. https://doi.org/10.3390/pharmaceutics16030402

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, *13*(17), 4287. https://doi.org/10.3390/cancers13174287

MacFarlane, L., & Murphy, P. R. (2010). MicroRNA: biogenesis, function and role in cancer. *Current Genomics*, *11*(7), 537–561. https://doi.org/10.2174/138920210793175895

Machowska, M., Galka-Marciniak, P., & Kozlowski, P. (2022). Consequences of genetic variants in miRNA genes. *Computational and Structural Biotechnology Journal*, *20*, 6443–6457. https://doi.org/10.1016/j.csbj.2022.11.036

Mahmoud, R., Ordóñez-Morán, P., & Allegrucci, C. (2022). Challenges for triple negative breast cancer treatment: Defeating heterogeneity and cancer stemness. *Cancers*, *14*(17), 4280. https://doi.org/10.3390/cancers14174280

Marsico, A., Huska, M. R., Lasserre, J., Hu, H., Vucicevic, D., Musahl, A., Orom, U. A., & Vingron, M. (2013). PROmiRNA: a new miRNA promoter recognition method uncovers the complex regulation of intronic miRNAs. *Genome Biology*, *14*(8). https://doi.org/10.1186/gb-2013-14-8-r84

Martins, T. S., Catita, J., Rosa, I. M., Da Cruz E Silva, O. a. B., & Henriques, A. G. (2018). Exosome isolation from distinct biofluids using precipitation and column-based approaches. *PLoS ONE*, *13*(6), e0198820. https://doi.org/10.1371/journal.pone.0198820

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., Stivala, F., Libra, M., Basecke, J., Evangelisti, C., Martelli, A. M., & Franklin, R. A. (2006). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research*, *1773*(8), 1263–1284. https://doi.org/10.1016/j.bbamcr.2006.10.001

Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022). MIRNA: a promising therapeutic target in cancer. *International Journal of Molecular Sciences*, *23*(19), 11502. https://doi.org/10.3390/ijms231911502

Momenimovahed, Z., & Salehiniya, H. (2019). <p>Epidemiological characteristics of and risk factors for breast cancer in the world</p> *Breast Cancer Targets and Therapy*, *Volume 11*, 151–164. https://doi.org/10.2147/bctt.s176070

Morales-Kastresana, A., & Jones, J. C. (2016). Flow cytometric analysis of extracellular vesicles. *Methods in Molecular Biology*, 215–225. https://doi.org/10.1007/978-1-4939-6728-5_16

Mustafa, M., Ahmad, R., Tantry, I. Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin, N., Hassan, M. I., Habib, S., & Islam, S. (2024). Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. *Cells*, *13*(22), 1838. https://doi.org/10.3390/cells13221838

Nalbantsoy, A., Karabay-Yavasoglu, N., Sayim, F., Deliloglu-Gurhan, I., Gocmen, B., Arikan, H., & Yildiz, M. (2012). Determination of in vivo toxicity and in vitro cytotoxicity of venom from the Cypriot blunt-nosed viper Macrovipera lebetina lebetina and antivenom production. *the Journal of Venomous Animals and Toxins Including Tropical Diseases*, *18*(2), 208–216. https://doi.org/10.1590/s1678-91992012000200011

Nedeljković, M., & Damjanović, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How we can rise to the challenge. *Cells*, *8*(9), 957. https://doi.org/10.3390/cells8090957

Nilasari, F., Haryana, S. M., Nugrahaningsih, D. a. A., & Satriyo, P. B. (2024). Development of nanocomplex mimic-hsa-miR-143-3p loaded exosome (exo-miR) to inhibit viability, migration and proliferation of triple-negative breast cancer. *Indonesian Journal of Biotechnology*, *29*(4), 190. https://doi.org/10.22146/ijbiotech.92817

Nogimori, T., Furutachi, K., Ogami, K., Hosoda, N., & Hoshino, S. (2019). A novel method for stabilizing microRNA mimics. *Biochemical and Biophysical Research Communications*, *511*(2), 422–426. https://doi.org/10.1016/j.bbrc.2019.02.075

Noh, J., Mun, S., Lim, E. H., Kim, H., Chang, D., Hur, J., & Yee, S. (2021). Induction of Apoptosis in MDA-MB-231 Cells Treated with the Methanol Extract of Lichen Physconia hokkaidensis. *Journal of Fungi*, *7*(3), 188. https://doi.org/10.3390/jof7030188

Nössing, C., & Ryan, K. M. (2022). 50 years on and still very much alive: 'Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.' *British Journal of Cancer*, *128*(3), 426–431. https://doi.org/10.1038/s41416-022-02020-0

Nussinov, R., Jang, H., Tsai, C., Liao, T., Li, S., Fushman, D., & Zhang, J. (2017). Intrinsic protein disorder in oncogenic KRAS signaling. *Cellular and Molecular Life Sciences*, *74*(17), 3245–3261. https://doi.org/10.1007/s00018-017-2564-3

Obeng, E. (2020). Apoptosis (programmed cell death) and its signals - A review. *Brazilian Journal of Biology*, *81*(4), 1133–1143. https://doi.org/10.1590/1519-6984.228437

Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple negative breast cancer Treatment Options and Limitations: Future outlook. *Pharmaceutics*, *15*(7), 1796. https://doi.org/10.3390/pharmaceutics15071796

O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology*, *9*. https://doi.org/10.3389/fendo.2018.00402

O'Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., & McCann, A. (2015). The fate of chemoresistance in triple negative breast cancer (TNBC). *BBA Clinical*, *3*, 257–275. https://doi.org/10.1016/j.bbacli.2015.03.003

Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., & Ramírez-Valdespino, C. A. (2022). Subtypes of breast cancer. In *Breast Cancer* (pp. 31–42). https://doi.org/10.36255/exon-publications-breast-cancer-subtypes

Pan, W., Chai, B., Li, L., Lu, Z., & Ma, Z. (2023). p53/MicroRNA-34 axis in cancer and beyond. *Heliyon*, *9*(4), e15155. https://doi.org/10.1016/j.heliyon.2023.e15155

Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2022). Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. *Clinical Cancer Research*, *29*(1), 30–39. https://doi.org/10.1158/1078-0432.ccr-22-1366

Patra, S., Young, V., Llewellyn, L., Senapati, J. N., & Mathew, J. (2017). BRAF, KRAS and PIK3CA mutation and sensitivity to trastuzumab in breast cancer cell line model. *PubMed*, *18*(8), 2209–2213. https://doi.org/10.22034/apjcp.2017.18.8.2209

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., Williams, L. J., Deng, W., Chen, G., Mbofung, R., Lazar, A. J., Torres-Cabala, C. A., Cooper, Z. A., Chen, P., Tieu, T. N., . . . Hwu, P. (2015). Loss of PTEN promotes resistance to T Cell–Mediated immunotherapy. *Cancer Discovery*, *6*(2), 202–216. https://doi.org/10.1158/2159-8290.cd-15-0283

Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. *Signal Transduction and Targeted Therapy*, *1*(1). https://doi.org/10.1038/sigtrans.2015.4

Pereira, A. a. R., Assis, R. J. F., Da Costa Pereira, E., Lima, V. C., Nugue, P. B., & Pereira, J. R. (2013). Cisplatin, gemcitabine, and vinorelbine (PGV) compared with cisplatin and etoposide (PE) in the first-line treatment of extensive-stage small-cell lung cancer: Two Brazilian institution experience. *Journal of Clinical Oncology*, *31*(15_suppl), e18548. https://doi.org/10.1200/jco.2013.31.15_suppl.e18548

Piasecka, D., Braun, M., Kordek, R., Sadej, R., & Romanska, H. (2018). MicroRNAs in regulation of triple-negative breast cancer progression. *Journal of Cancer Research and Clinical Oncology*, *144*(8), 1401–1411. https://doi.org/10.1007/s00432-018-2689-2

Pinweha, P., Phillips, C. A., Gregory, P. A., Li, X., Chuayboonya, P., Mongkolsiri, P., Goodall, G. J., & Jitrapakdee, S. (2019). MicroRNA-143-3p targets pyruvate carboxylase expression and controls proliferation and migration of MDA-MB-231 cells. *Archives of Biochemistry and Biophysics*, *677*, 108169. https://doi.org/10.1016/j.abb.2019.108169

Prabhu, K. S., Sadida, H. Q., Kuttikrishnan, S., Junejo, K., Bhat, A. A., & Uddin, S. (2024). Beyond genetics: Exploring the role of epigenetic alterations in breast cancer. *Pathology - Research and Practice*, *254*, 155174. https://doi.org/10.1016/j.prp.2024.155174

Qian, H., Tay, C. Y., Setyawati, M. I., Chia, S. L., Lee, D. S., & Leong, D. T. (2016). Protecting microRNAs from RNase degradation with steric DNA nanostructures. *Chemical Science*, *8*(2), 1062–1067. https://doi.org/10.1039/c6sc01829g

Qian, Y., Teng, Y., Li, Y., Lin, X., Guan, M., Li, Y., Cao, X., & Gao, Y. (2019). MiR-143-3p suppresses the progression of nasal squamous cell carcinoma by targeting Bcl-2 and IGF1R. *Biochemical and Biophysical Research Communications*, *518*(3), 492–499. https://doi.org/10.1016/j.bbrc.2019.08.075

Ren, Y., Han, X., Yu, K., Sun, S., Zhen, L., Li, Z., & Wang, S. (2014). microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. *Molecular Medicine Reports*, *10*(1), 315–321. https://doi.org/10.3892/mmr.2014.2222

Rieger, A. M., Nelson, K. L., Konowalchuk, J. D., & Barreda, D. R. (2011). Modified Annexin V/Propidium iodide apoptosis assay for accurate assessment of cell death. *Journal of Visualized Experiments*, *50*. https://doi.org/10.3791/2597

Riyanda, V. B., Rudiman, N. R., & Usman, N. N. (2021). Programmed Death-Ligand 1 Protein and Colorectal Cancer Patient Survival Rates n Hasan Sadikin Hospital Bandung. *Bioscientia Medicina Journal of Biomedicine and Translational Research*, *6*(1), 1300–1306. https://doi.org/10.37275/bsm.v6i1.437

Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018). DNA repair pathways and cisplatin resistance: an intimate relationship. *Clinics*, *73*, e478s. https://doi.org/10.6061/clinics/2018/e478s

Rusiecka, B., Piwocka, O., & Knopik-Skrocka, A. (n.d.). *Response of MDA-MB231 cells to* cisplatin *and paclitaxel — viability, migration and gene expression estimation in mono- and co-culture with macrophages*. Rusiecka | Reports of Practical Oncology and Radiotherapy. Retrieved July 17, 2025, from https://journals.viamedica.pl/rpor/article/view/106149

Samaan, T. M. A., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019). Paclitaxel's mechanistic and clinical effects on breast cancer. *Biomolecules*, *9*(12), 789. https://doi.org/10.3390/biom9120789

Sánchez-Díez, M., Romero-Jiménez, P., Alegría-Aravena, N., Gavira-O'Neill, C. E., Vicente-García, E., Quiroz-Troncoso, J., González-Martos, R., Ramírez-Castillejo, C., & Pastor, J. M. (2025). Assessment of cell viability in Drug therapy: IC50 and other new Time-Independent Indices for evaluating Chemotherapy efficacy. *Pharmaceutics*, *17*(2), 247. https://doi.org/10.3390/pharmaceutics17020247

Sánchez-Rivera, F. J., Ryan, J., Soto-Feliciano, Y. M., Beytagh, M. C., Xuan, L., Feldser, D. M., Hemann, M. T., Zamudio, J., Dimitrova, N., Letai, A., & Jacks, T. (2021). Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. *Proceedings of the National Academy of Sciences*, *118*(23). https://doi.org/10.1073/pnas.2019740118

Sasich, L. D., & Sukkari, S. R. (2011). The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). *Saudi Pharmaceutical Journal*, *20*(4), 381–385. https://doi.org/10.1016/j.jsps.2011.12.001

Savas, P., Lo, L. L., Luen, S. J., Blackley, E. F., Callahan, J., Moodie, K., Van Geelen, C. T., Ko, Y., Weng, C., Wein, L., Silva, M. J., Bujak, A. Z., Yeung, M. M., Ftouni, S., Hicks, R. J., Francis, P. A., Lee, C. K., Dawson, S., & Loi, S. (2022). Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: a Phase II study. *Cancer Discovery*, *12*(9), 2058–2073. https://doi.org/10.1158/2159-8290.cd-21-1696

Sawant, S., Prakruthi, J., Daddi, A., Ghosh, J., Joshi, A., & Dhir, A. (2015). Cisplatin-induced cardiotoxicity – two case reports. *OncoReview*, *5*(4), 145–150. https://doi.org/10.5604/20828691.1189719

Schrödl, K., Oelmez, H., Edelmann, M., Huber, R. M., & Bergner, A. (2009). Altered Ca2+-homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells. *PubMed*. https://doi.org/10.3233/clo-2009-0472

Sharma, V., & Mukhopadhyay, C. D. (2023). Exosome as drug delivery system: Current advancements. *Extracellular Vesicle*, *3*, 100032. https://doi.org/10.1016/j.vesic.2023.100032

Silva, M. M., Rocha, C. R. R., Kinker, G. S., Pelegrini, A. L., & Menck, C. F. M. (2019). The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. *Scientific Reports*, *9*(1). https://doi.org/10.1038/s41598-019-54065-6

Sinnarkar, S., Suryawanshi, P., Dilip, A., Bhawalkar, J., & Ladke, V. (2024). Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer. *Journal of the Egyptian National Cancer Institute*, *36*(1). https://doi.org/10.1186/s43046-024-00246-y

Skotland, T., Hessvik, N. P., Sandvig, K., & Llorente, A. (2018). Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. *Journal of Lipid Research*, *60*(1), 9–18. https://doi.org/10.1194/jlr.r084343

Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022). Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers*, *14*(10), 2569. https://doi.org/10.3390/cancers14102569

Stelling-Férez, J., Cappellacci, I., Pandolfi, A., Gabaldón, J. A., Pipino, C., & Nicolás, F. J. (2023). Oleanolic acid rescues critical features of umbilical vein endothelial cells permanently affected by hyperglycemia. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1308606

Stockert, J. C., Horobin, R. W., Colombo, L. L., & Blázquez-Castro, A. (2018). Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives. *Acta Histochemica*, *120*(3), 159–167. https://doi.org/10.1016/j.acthis.2018.02.005

Sudnitsyna, J., Skverchinskaya, E., Dobrylko, I., Nikitina, E., Gambaryan, S., & Mindukshev, I. (2020). Microvesicle formation induced by oxidative stress in human erythrocytes. *Antioxidants*, *9*(10), 929. https://doi.org/10.3390/antiox9100929

Svoronos, A. A., Engelman, D. M., & Slack, F. J. (2016). OnCOMIR or *tumor suppressor*? The duplicity of MicroRNAs in cancer. *Cancer Research*, *76*(13), 3666–3670. https://doi.org/10.1158/0008-5472.can-16-0359

Tanida, S., Mizoshita, T., Ozeki, K., Tsukamoto, H., Kamiya, T., Kataoka, H., Sakamuro, D., & Joh, T. (2012). Mechanisms of Cisplatin-Induced apoptosis and of Cisplatin sensitivity: Potential of BIN1 to act as a potent predictor of Cisplatin sensitivity in gastric cancer treatment. *International Journal of Surgical Oncology*, *2012*, 1–8. https://doi.org/10.1155/2012/862879

Tavanafar, F., Safaralizadeh, R., Hosseinpour-Feizi, M. A., Mansoori, B., Shanehbandi, D., Mohammadi, A., & Baradaran, B. (2017). Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors. *Biomedicine & Pharmacotherapy*, *91*, 920–924. https://doi.org/10.1016/j.biopha.2017.04.119

Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021). Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. *Journal of Experimental Pharmacology*, *Volume 13*, 303–328. https://doi.org/10.2147/jep.s267383

Thompson, W., & Papoutsakis, E. T. (2023). The role of biomechanical stress in extracellular vesicle formation, composition and activity. *Biotechnology Advances*, *66*, 108158. https://doi.org/10.1016/j.biotechadv.2023.108158

Tkaczuk, K., & Yared, J. (2012). Update on taxane development: new analogs and new formulations. *Drug Design Development and Therapy*, 371. https://doi.org/10.2147/dddt.s28997

Tokumaru, Y., Takabe, K., Yoshida, K., & Akao, Y. (2020). Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. *Cancer Science*, *111*(4), 1076–1083. https://doi.org/10.1111/cas.14357

Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O'Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., Nanda, R., Gucalp, A., Awada, A., Garcia-Estevez, L., Trudeau, M. E., Steinberg, J., Uppal, H., Tudor, I. C., Peterson, A., & Cortes, J. (2018). Enzalutamide for the treatment of androgen Receptor–Expressing Triple-Negative breast Cancer. *Journal of Clinical Oncology*, *36*(9), 884–890. https://doi.org/10.1200/jco.2016.71.3495

Tsujino, T., Sugito, N., Taniguchi, K., Honda, R., Komura, K., Yoshikawa, Y., Takai, T., Minami, K., Kuranaga, Y., Shinohara, H., Tokumaru, Y., Heishima, K., Inamoto, T., Azuma, H., & Akao, Y. (2019). MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. *Cancer Science*, *110*(7), 2189–2199. https://doi.org/10.1111/cas.14035

Umar, A. K. (2022). Stem cell's Secretome delivery systems. *Advanced Pharmaceutical Bulletin*, *13*(2), 244–258. https://doi.org/10.34172/apb.2023.027

Verschoor, C. P., Lelic, A., Bramson, J. L., & Bowdish, D. M. E. (2015). An introduction to Automated flow cytometry gating tools and their implementation. *Frontiers in Immunology*, *6*. https://doi.org/10.3389/fimmu.2015.00380

Wang, F., Cerione, R. A., & Antonyak, M. A. (2021). Isolation and characterization of extracellular vesicles produced by cell lines. *STAR Protocols*, *2*(1), 100295. https://doi.org/10.1016/j.xpro.2021.100295

Wang, S., Zhang, Q., Zhang, T., & Mao, X. (2024). Invasive papillary carcinoma of the breast: A case report. *Oncology Letters*, *28*(1). https://doi.org/10.3892/ol.2024.14433

Wang, Y., Xu, X., Yu, S., Jeong, K. J., Zhou, Z., Han, L., Tsang, Y. H., Li, J., Chen, H., Mangala, L. S., Yuan, Y., Eterovic, A. K., Lu, Y., Sood, A. K., Scott, K. L., Mills, G. B., & Liang, H. (2017). Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. *Genome Research*, *27*(7), 1112–1125. https://doi.org/10.1101/gr.219741.116

Wang, Y., Zhao, L., Xiang, Z., Zhou, X., Gui, Y., & He, C. (2012). Correlation analysis of the results of double fluorescence (AO/PI) staining and clinical outcomes. *Journal of Reproduction and Contraception*, *23*(2), 111–118. https://doi.org/10.1016/s1001-7844(13)60013-9

Wang, Z., Wang, C., Liu, W., & Ai, Z. (2019). Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation, invasion, and migration of papillary thyroid carcinoma cells by targeting MSI2. *Experimental and Molecular Pathology*, *112*, 104342. https://doi.org/10.1016/j.yexmp.2019.104342

Watanabe, Y., Tsuchiya, A., & Terai, S. (2020). The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. *Clinical and Molecular Hepatology*, *27*(1), 70–80. https://doi.org/10.3350/cmh.2020.0194

Won, K., & Spruck, C. (2020). Triple-negative breast cancer therapy: Current and future perspectives (Review). *International Journal of Oncology*, *57*(6), 1245–1261. https://doi.org/10.3892/ijo.2020.5135

Wu, J., Zhu, Y., Liu, D., Cong, Q., & Bai, C. (2024). Biological functions and potential mechanisms of miR-143-3p in cancers (Review). *Oncology Reports*, *52*(3). https://doi.org/10.3892/or.2024.8772

Wu, Y., Zhou, C., Liam, C., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., Huang, C., Qin, S., Zhu, Y., Pan, H., Liang, H., Li, E., Jiang, G., How, S., Fernando, M., . . . Zuo, Y. (2015). First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Annals of Oncology*, *26*(9), 1883–1889. https://doi.org/10.1093/annonc/mdv270

Xia, C., Yang, Y., Kong, F., Kong, Q., & Shan, C. (2018). MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. *Biochimie*, *147*, 98–104. https://doi.org/10.1016/j.biochi.2018.01.003

Xie, F., Li, C., Zhang, X., Peng, W., & Wen, T. (2019). MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. *Biomedicine & Pharmacotherapy*, *119*, 109424. https://doi.org/10.1016/j.biopha.2019.109424

Xie, Q., Zheng, J., Ding, J., Wu, Y., Liu, L., Yu, Z., & Chen, G. (2022). Exosome-Mediated immunosuppression in tumor microenvironments. *Cells*, *11*(12), 1946. https://doi.org/10.3390/cells11121946

Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., Shao, Z., & Yu, K. (2025). Breast cancer: pathogenesis and treatments. *Signal Transduction and Targeted Therapy*, *10*(1). https://doi.org/10.1038/s41392-024-02108-4

Yan, F., Pang, J., Peng, Y., Molina, J. R., Yang, P., & Liu, S. (2016). Elevated cellular PD1/PD-L1 expression confers acquired resistance to cisplatin in small cell lung cancer cells. *PLoS ONE*, *11*(9), e0162925. https://doi.org/10.1371/journal.pone.0162925

Yang, T., Kang, L., Li, D., & Song, Y. (2023). Immunotherapy for HER-2 positive breast cancer. *Frontiers in Oncology*, *13*. https://doi.org/10.3389/fonc.2023.1097983

Yang, Z., Wang, J., Pan, Z., & Zhang, Y. (2018). miR-143-3p regulates cell proliferation and apoptosis by targeting IGF1R and IGFBP5 and regulating the Ras/p38 MAPK signaling pathway in rheumatoid arthritis. *Experimental and Therapeutic Medicine*. https://doi.org/10.3892/etm.2018.5907

Yin, L., Duan, J., Bian, X., & Yu, S. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*, *22*(1). https://doi.org/10.1186/s13058-020-01296-5

Yu, Y., Nangia-Makker, P., Farhana, L., Rajendra, S. G., Levi, E., & Majumdar, A. P. N. (2015). miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. *Molecular Cancer*, *14*(1). https://doi.org/10.1186/s12943-015-0372-7

Zerdan, M. B., Ghorayeb, T., Saliba, F., Allam, S., Zerdan, M. B., Yaghi, M., Bilani, N., Jaafar, R., & Nahleh, Z. (2022). Triple negative breast Cancer: Updates on classification and treatment in 2021. *Cancers*, *14*(5), 1253. https://doi.org/10.3390/cancers14051253

Zhang, D., Lee, H., Zhu, Z., Minhas, J. K., & Jin, Y. (2016). Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. *AJP Lung Cellular and Molecular Physiology*, *312*(1), L110–L121. https://doi.org/10.1152/ajplung.00423.2016

Zhang, F., & Cao, H. (2018). MicroRNA-143-3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the k-Ras/Raf/MEK/ERK signaling pathway. *International Journal of Oncology*. https://doi.org/10.3892/ijo.2018.4655

Zhang, H., Zang, C., Zhao, W., Zhang, L., Liu, R., Feng, Z., Wu, J., & Cui, R. (2023). Exosome Derived from Mesenchymal Stem Cells Alleviates Hypertrophic Scar by Inhibiting the Fibroblasts via TNFSF-13/HSPG2 Signaling Pathway. *International Journal of Nanomedicine*, *Volume 18*, 7047–7063. https://doi.org/10.2147/ijn.s433510

Zhang, Y., Lv, Z., & He, Q. (2022). Agmatine alleviates Cisplatin-Induced ototoxicity by activating PI3K/AKT signaling pathway. *eNeuro*, *9*(2), ENEURO.0434-21.2022. https://doi.org/10.1523/eneuro.0434-21.2022

Zhou, L., Dong, J., Huang, G., Sun, Z., & Wu, J. (2017). MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer. *Brazilian Journal of Medical and Biological Research*, *50*(8). https://doi.org/10.1590/1414-431x20175891

Zullo, J., Matsumoto, K., Xavier, S., Ratliff, B., & Goligorsky, M. S. (2015). The cell secretome, a mediator of cell-to-cell communication. *Prostaglandins & Other Lipid Mediators*, *120*, 17–20. https://doi.org/10.1016/j.prostaglandins.2015.03.012